Showing 541 - 560 results of 100,892 for search '(( 5 non decrease ) OR ( 5 ((wt decrease) OR (((mean decrease) OR (a decrease)))) ))', query time: 1.69s Refine Results
  1. 541
  2. 542
  3. 543
  4. 544
  5. 545
  6. 546

    Decreased biomechanical stability of bones from <i>Col1a1-Krm2</i> transgenic mice. by Jochen Schulze (365258)

    Published 2013
    “…(D) Cortical thickness (C.Th.) and bone mineral density (vBMD) are decreased in <i>Col1a1-Krm2</i> transgenic mice compared to wildtype littermates. …”
  7. 547

    List of Included studies. by Zahra Tajik (20752452)

    Published 2025
    “…There is no significant difference one month after NSPT in diabetic patients (SMD: -5.83, 95%CI: -15.5, 3.83, p = 0.237, I-square, 97.4%, random effects model, n = 2), but three (SMD: -2.44, 95%CI: -3.37, -1.15, p = 0.001, I-square, 75.9%, random effects model, n = 3) and six months (SMD: -2.41, 95%CI: -3.81, -1.01, p = 0.001, I-square, 78.7%, random effects model, n = 2) after the treatment, a significant decrease is observed in the mean GCF visfatin level. …”
  8. 548

    The search strategy in three databases. by Zahra Tajik (20752452)

    Published 2025
    “…There is no significant difference one month after NSPT in diabetic patients (SMD: -5.83, 95%CI: -15.5, 3.83, p = 0.237, I-square, 97.4%, random effects model, n = 2), but three (SMD: -2.44, 95%CI: -3.37, -1.15, p = 0.001, I-square, 75.9%, random effects model, n = 3) and six months (SMD: -2.41, 95%CI: -3.81, -1.01, p = 0.001, I-square, 78.7%, random effects model, n = 2) after the treatment, a significant decrease is observed in the mean GCF visfatin level. …”
  9. 549

    NIH score. by Zahra Tajik (20752452)

    Published 2025
    “…There is no significant difference one month after NSPT in diabetic patients (SMD: -5.83, 95%CI: -15.5, 3.83, p = 0.237, I-square, 97.4%, random effects model, n = 2), but three (SMD: -2.44, 95%CI: -3.37, -1.15, p = 0.001, I-square, 75.9%, random effects model, n = 3) and six months (SMD: -2.41, 95%CI: -3.81, -1.01, p = 0.001, I-square, 78.7%, random effects model, n = 2) after the treatment, a significant decrease is observed in the mean GCF visfatin level. …”
  10. 550

    List of excluded studies. by Zahra Tajik (20752452)

    Published 2025
    “…There is no significant difference one month after NSPT in diabetic patients (SMD: -5.83, 95%CI: -15.5, 3.83, p = 0.237, I-square, 97.4%, random effects model, n = 2), but three (SMD: -2.44, 95%CI: -3.37, -1.15, p = 0.001, I-square, 75.9%, random effects model, n = 3) and six months (SMD: -2.41, 95%CI: -3.81, -1.01, p = 0.001, I-square, 78.7%, random effects model, n = 2) after the treatment, a significant decrease is observed in the mean GCF visfatin level. …”
  11. 551
  12. 552
  13. 553
  14. 554

    Decreased proliferation and increased apoptosis in <i>Mab21l2</i> mutant embryos. by Yohei Saito (180130)

    Published 2012
    “…<p>(A–F) BrdU assay on transverse paraffin sections of E11.5 WT and <i>Mab21l2</i> mutant (−/−) embryos. …”
  15. 555
  16. 556
  17. 557

    Reduction of SIRT1 during DNA damage decreases the number of silent clones that have methylation. by Heather M. O'Hagan (271283)

    Published 2008
    “…One representative bisulfite sequenced clone is presented for each HSVTK silent clone. (B) A dot plot of the mean number of CpGs methylated per HSVTK silenced clone from either un-siRNA treated cells (untreated) (<a href="http://www.plosgenetics.org/article/info:doi/10.1371/journal.pgen.1000155#pgen-1000155-g005" target="_blank">Figure 5D & E</a>), non-target siRNA treated cells (NT), or SIRT1 siRNA treated cells (SIRT1). …”
  18. 558
  19. 559
  20. 560